Armata Pharmaceuticals Enters Secured Credit Agreement With Innoviva Strategic Opportunities, A Wholly-owned Subsidiary Of Innoviva
Armata Pharmaceuticals Enters Secured Credit Agreement With Innoviva Strategic Opportunities, A Wholly-owned Subsidiary Of Innoviva
Armata Pharmicals 與 Innoviva 的全資子公司 Innoviva Strategic Opportunities 簽訂擔保信貸協議
The gross proceeds to be received by the Company at closing are $35 million before deducting transaction-related expenses. Proceeds from the $35 million new financing transaction will be used to advance the Company's lead therapeutic phage candidates, including AP‐PA02 and AP‐SA02, which target infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.
在扣除交易相關費用之前，公司在收盤時收到的總收益爲3500萬美元。這筆3500萬美元新融資交易的收益將用於推進公司主要的候選治療噬菌體，包括針對由以下原因引起的感染的AP‐PA02和AP‐SA02 銅綠假單胞菌 和 金黃色葡萄球菌，分別地。